A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy

Programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD-1/PD-L1 inhibitors are associated with a low response rate and are only effective on a small number of patient...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Med Rep
Autori principali: Kong, Xianbin, Lu, Peng, Liu, Chuanxin, Guo, Yuzhu, Yang, Yuying, Peng, Yingying, Wang, Fangyuan, Bo, Zhichao, Dou, Xiaoxin, Shi, Haoyang, Meng, Jingyan
Natura: Artigo
Lingua:Inglês
Pubblicazione: D.A. Spandidos 2021
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7985997/
https://ncbi.nlm.nih.gov/pubmed/33760188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2021.12001
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi